MASAC Issues a Safety Information Update on HEMLIBRA

On April 24, 2018 the Medical and Scientific Advisory Council (MASAC) of the NHF issued a Safety Information Update on HEMLIBRA. This was to notify the community that one clinical trial participant had developed an antibody against HEMLIBRA and had to stop taking it. The reaction to HEMLIBRA did not cause him to develop an inhibitor against factor. You can read the full update here: https://www.hemophilia.org/Newsroom/Medical-News/MASAC-Safety-Information-Update-on-Emicizumab-HEMLIBRA.